BenevolentAI Analyst & Investor Event September 2022

London, September 27, 2022

BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The Benevolent Platform™ powers a growing in-house pipeline of over 20 disease programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

RSVP for Event / Log Back in Presenter Access

Additional menu options can be found in the menu bar on the left or at the top.

BenevolentAI [BAI.AS]
With sev­er­al suc­cess­ful col­lab­o­ra­tions with lead­ing phar­ma­ceu­ti­cal or­gan­i­sa­tions, they are the on­ly AI-drug dis­cov­ery com­pany with a clin­i­cal­ly vali­dat­ed ap­proach, hav­ing dis­cov­ered a lead­ing re­pur­posed drug can­di­date for COVID-19. [more in­for­ma­tion]

Event Contact

Emily White
Solebury Trout